title: Non-invasive imaging of phosphoinositide-3-kinase-catalytic-subunit-alpha (PIK3CA) promoter modulation in small animal models.
abstract: Activation of the PI3K/Akt pathway, a critical step for survival in cancer cells is often associated with decreased sensitivity to several chemotherapeutic drugs. PIK3CA gene amplification is observed in 16-24% of epithelial ovarian cancer (EOC) patients in conjunction with p53 mutations. A 900 bp long PIK3CA promoter is shown to be negatively regulated by p53 in ovarian surface epithelial cells but the consequence of chemotherapeutic drug treatments on this promoter in ovarian cancer cells is largely unknown. We aim to study the modulation of this promoter by cisplatin using an improved fusion reporter in ovarian cancer cells and tumor xenografts by non-invasive imaging approach. A PIK3CA sensor was developed using a bi-fusion reporter from a newly constructed library of bi- and tri-fusion vectors comprising of two mutant far red fluorescent proteins (mcherry/mch and tdTomato/tdt), a mutant firefly luciferase (fluc2), and a PET reporter protein (ttk). In vivo imaging of mice implanted with 293T cells transiently expressing these bi- and tri-fusion reporters along with respective controls revealed comparable activity of each reporter in the fusion background and fluc2-tdt as the most sensitive one. Repression of the PIK3CA sensor by drugs was inversely proportional to cellular p53 level in a germline (PA1) and in an EOC (A2780) cell line but not in a p53 deficient EOC (SKOV3) cell line. Bioluminescence imaging of tumor xenografts stably expressing the PIK3CA sensor in PA1 and A2780 cells exhibited attenuating activity without any change in SKOV3 tumors expressing the PIK3CA sensor after cisplatin treatment. Sequential mutation at p53 binding sites showed gradual increase in promoter activity and decreased effects of the drugs. These newly developed PIK3CA-fluc2-tdt and the mutant reporter sensors thus would be extremely useful for screening new drugs and for functional assessment of PIK3CA expression from intact cells to living subjects.
authors: Advanced Centre for Treatment, Research and Education in Cancer-ACTREC, Tata Memorial Centre, Navi Mumbai, Maharashtra, India.
authors: Snehal M
authors: SM
authors: Gaikwad
authors: Lata
authors: L
authors: Gunjal
authors: Anitha R
authors: AR
authors: Junutula
authors: Arezoo
authors: A
authors: Astanehe
authors: Sanjiv Sam
authors: SS
authors: Gambhir
authors: Pritha
authors: P
authors: Ray
mesh_terms: D000818:Animals; D001665:Binding Sites; D015153:Blotting, Western; D002460:Cell Line; D005434:Flow Cytometry; D005455:Fluorescent Antibody Technique; D006801:Humans; D051379:Mice; D019869:Phosphatidylinositol 3-Kinases / Q000235:genetics*; D049268:Positron-Emission Tomography; D011401:Promoter Regions, Genetic / Q000235:genetics*
chemical_list: D019869:Phosphatidylinositol 3-Kinases
references: Reprod Biol Endocrinol. 2003 Oct 07;1:66
references: 14609433
references: Bioconjug Chem. 2004 Nov-Dec;15(6):1376-88
references: 15546205
references: PLoS One. 2008 Mar 12;3(3):e1758
references: 18335034
references: Brief Funct Genomics. 2010 Mar;9(2):129-38
references: 20093306
references: Cancer Res. 2004 Feb 15;64(4):1323-30
references: 14973078
references: J Cell Sci. 2008 Mar 1;121(Pt 5):664-74
references: 18270270
references: Oncogene. 2010 Jan 7;29(1):11-25
references: 19802016
references: Nat Methods. 2008 Jun;5(6):545-51
references: 18454154
references: Oncogene. 2003 Oct 20;22(47):7265-79
references: 14576837
references: Nat Rev Cancer. 2003 Jul;3(7):502-16
references: 12835670
references: Genes Dev. 2003 Mar 1;17(5):545-80
references: 12629038
references: Cancer Res. 2007 Apr 1;67(7):3085-93
references: 17409415
references: Proc Natl Acad Sci U S A. 2005 Nov 29;102(48):17412-7
references: 16293690
references: Biol Chem. 2004 May;385(5):353-61
references: 15195994
references: Ann Nucl Med. 2006 Apr;20(3):165-70
references: 16715945
references: Neoplasia. 2006 Oct;8(10):796-806
references: 17032496
references: Clin Cancer Res. 2008 Sep 15;14(18):5801-9
references: 18794090
references: Int J Radiat Oncol Biol Phys. 1999 Jul 15;44(5):1119-24
references: 10421546
references: Nat Rev Cancer. 2010 May;10(5):342-52
references: 20414202
references: Cancer Res. 2004 Nov 1;64(21):7678-81
references: 15520168
references: Nature. 2011 Jun 29;474(7353):609-15
references: 21720365
references: Nat Rev Cancer. 2002 Jul;2(7):489-501
references: 12094235
references: Oncogene. 2005 Feb 17;24(8):1477-80
references: 15608678
references: Circulation. 2006 Feb 21;113(7):1005-14
references: 16476845
references: Oncogene. 2001 Jun 28;20(29):3806-13
references: 11439344
references: Oncogene. 2008 Sep 18;27(41):5497-510
references: 18794884
references: Physiol Rev. 2010 Jul;90(3):1103-63
references: 20664080
references: Cancer Biol Ther. 2009 Jan;8(1):21-6
references: 19029838
references: Am J Nucl Med Mol Imaging. 2012;2(4):418-31
references: 23145359
references: Cancer Res. 2003 Mar 15;63(6):1160-5
references: 12649169
references: Semin Nucl Med. 2001 Oct;31(4):312-20
references: 11710773
references: Nat Rev Cancer. 2005 Dec;5(12):921-9
references: 16341083
references: J Biomed Opt. 2007 Nov-Dec;12(6):064025
references: 18163841
references: Curr Opin Biotechnol. 2007 Feb;18(1):31-7
references: 17254764
references: Science. 2003 Apr 4;300(5616):87-91
references: 12677058